Protein binding displacement interactions and their clinical importance
- PMID: 6345130
- DOI: 10.2165/00003495-198325050-00003
Protein binding displacement interactions and their clinical importance
Abstract
The binding of drugs to proteins is an important pharmacokinetic parameter. Many methods are available for the study of drug protein binding phenomena and there are also many ways to interpret the binding data. Although much emphasis has been placed on the binding of drugs in the plasma, binding also takes place in the tissues. Displacement interactions involving plasma or tissue binding sites have been implicated as the causative mechanisms in many drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interactions. However, the importance of plasma binding displacement as a mechanism of drug interaction has been overestimated and overstated, being based largely on in vitro data. Because displaced drug can normally distribute out of the plasma compartment, increases of free drug concentrations are usually transient and therefore will not give rise to changed pharmacological effects in the patient. Those clinically important drug interactions formerly considered to be caused via displacement from plasma binding sites usually have another interaction mechanism involved; commonly decreased metabolism or renal elimination also takes place. Plasma binding displacement interactions, however, do become important clinically in certain specific situations, namely, when the displacing drug is administered quickly to the patient by the intravenous route, during therapeutic drug monitoring, and in certain drug disposition studies which involve the use of a heparin lock for blood sampling. Tissue binding displacement interactions have a greater potential to cause adverse effects in the patient as in this case drug will be forced from extravascular sites back into the plasma. The resulting increased drug plasma levels will lead to enhanced pharmacological effects and, possibly, frank toxicity. Displacement of drugs from binding sites simultaneously in both the plasma and in the tissues will combine the effects seen after displacement from the separate areas. Due to decreased binding in both areas, the free drug concentration in the plasma will increase leading to overactivity of the displaced drug.
Similar articles
-
Pharmacokinetic consequences of drug displacement from blood and tissue proteins.Clin Pharmacokinet. 1984 Jan;9 Suppl 1:32-41. doi: 10.2165/00003088-198400091-00005. Clin Pharmacokinet. 1984. PMID: 6705425
-
Drug interactions and clinical pharmacokinetics.Clin Pharmacokinet. 1976;1(5):351-72. doi: 10.2165/00003088-197601050-00003. Clin Pharmacokinet. 1976. PMID: 797504 Review.
-
Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites.Pharmacol Ther. 1982;17(2):211-20. doi: 10.1016/0163-7258(82)90012-2. Pharmacol Ther. 1982. PMID: 6757977 Review. No abstract available.
-
What is the true clinical significance of plasma protein binding displacement interactions?Drug Saf. 1995 Apr;12(4):227-33. doi: 10.2165/00002018-199512040-00001. Drug Saf. 1995. PMID: 7646820 Review. No abstract available.
-
Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.J Pharmacol Exp Ther. 1979 Sep;210(3):316-21. J Pharmacol Exp Ther. 1979. PMID: 480183
Cited by
-
Plasma protein binding of risperidone and its distribution in blood.Psychopharmacology (Berl). 1994 May;114(4):566-72. doi: 10.1007/BF02244986. Psychopharmacology (Berl). 1994. PMID: 7531854
-
Interpretation of drug levels in acute and chronic disease states.Clin Pharmacokinet. 1985 Nov-Dec;10(6):498-513. doi: 10.2165/00003088-198510060-00003. Clin Pharmacokinet. 1985. PMID: 3905165 Review.
-
The influence of binding to albumin and alpha 1-acid glycoprotein on the clearance of drugs by the liver.Pharm Weekbl Sci. 1987 Apr 24;9(2):65-74. doi: 10.1007/BF01960738. Pharm Weekbl Sci. 1987. PMID: 3295762 Review.
-
Binding of piroxicam to synovial fluid and plasma proteins in patients with rheumatoid arthritis.Eur J Clin Pharmacol. 1984;26(4):457-61. doi: 10.1007/BF00542141. Eur J Clin Pharmacol. 1984. PMID: 6734706
-
Development and Clinical Validation of Model-Informed Precision Dosing for Everolimus in Liver Transplant Recipients.ACS Pharmacol Transl Sci. 2024 Dec 12;8(1):216-224. doi: 10.1021/acsptsci.4c00581. eCollection 2025 Jan 10. ACS Pharmacol Transl Sci. 2024. PMID: 39816805
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical